Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Cullinan Therapeutics | 2024 | Post Ipo Equity | $280.0M | Cambridge |
| Alterome Therapeutics | 2024 | Series B | $132.0M | San Diego |
| Capstan Therapeutics | 2024 | Series B | $175.0M | San Diego |
| ImmPACT Bio | 2024 | Grant | $8.0M | Camarillo |
| Pinnacle Medicines | 2024 | Series A | $600K | Doylestown |
| Tyra Biosciences | 2024 | Post Ipo Equity | $200.0M | Carlsbad |
| Keros Therapeutics | 2024 | Post Ipo Equity | $140.0M | Lexington |
| SpringWorks Therapeutics | 2023 | Post Ipo Equity | $275.0M | Stamford |
| Koya Medical | 2023 | Series C | $30.0M | Oakland |
| Alpine Immune Sciences | 2023 | Post Ipo Equity | $150.0M | Seattle |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 151 | Cullinan Therapeutics | Post Ipo Equity | $280.0M | Cambridge, United States |
| 152 | Alterome Therapeutics | Series B | $132.0M | San Diego, United States |
| 153 | Capstan Therapeutics | Series B | $175.0M | San Diego, United States |
| 154 | ImmPACT Bio | Grant | $8.0M | Camarillo, United States |
| 155 | Pinnacle Medicines | Series A | $600K | Doylestown, United States |
| 156 | Tyra Biosciences | Post Ipo Equity | $200.0M | Carlsbad, United States |
| 157 | Keros Therapeutics | Post Ipo Equity | $140.0M | Lexington, United States |
| 158 | SpringWorks Therapeutics | Post Ipo Equity | $275.0M | Stamford, United States |
| 159 | Koya Medical | Series C | $30.0M | Oakland, United States |
| 160 | Alpine Immune Sciences | Post Ipo Equity | $150.0M | Seattle, United States |
Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.
Alterome Therapeutics is a biopharmaceutical company developing alteration-specific targeted therapies.
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.
Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases.
Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
Forward Therapeutics is a biopharma comapny targeting treatment of chronic inflammatory disorders.
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.
Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations.
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science.
Ikena Oncology develops differentiated therapies to target cancer growth and resistance, focusing on Hippo and RAS signaling pathways.
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.
Ruipeng Pet Hospital is a Shenzhen-based pet medical and beauty care hospital operator.
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
Immvira’s scientific objectives are based on numerous experimental designs of oHSV and outcomes of clinical trials.
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.
OrbiMed has invested in 239 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
OrbiMed's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 16 different industry categories.
Among tracked funding rounds, ACELYRIN received $300.0M in a Series C round. OrbiMed's total known invested capital is $12.2B.
OrbiMed's average investment size is $87.5M across its portfolio of 239 companies.
Recent OrbiMed portfolio additions include Cullinan Therapeutics, Alterome Therapeutics, Capstan Therapeutics, ImmPACT Bio, Pinnacle Medicines. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors